UPDATED: Merck’s PhIII Tredaptive trial flops as another cholesterol drug flunks out
Drugs KILL, Plants CURE…especially from a self admitted under US Department Of Justice Consent Decree Order “Criminal Organization” like MERCK, (“Mostly Evil Researchers! Crooks and
Kafkaesquers” per a former SVP or this overt death merchant brander).
~ Uncle Russ
Merck’s ($MRK) late-stage development effort suffered a major setback today as investigators announced that its huge Phase III trial of the “good” cholesterol drug Tredaptive–extended-release niacin/laropiprant–flunked its primary endpoint. Merck had enrolled more than 25,000 patients with a high risk for cardio events in the study but found no significant reduction in the risk of coronary deaths, nonfatal heart attacks, strokes or revascularizations compared with statin therapy.